Efficacy of Ecabet Sodium for Helicobacter pylori Eradication with Sequential Therapy
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
; : 180-185, 2018.
Article
en Ko
| WPRIM
| ID: wpr-738972
Biblioteca responsable:
WPRO
ABSTRACT
BACKGROUND/AIMS: We aimed to compare the outcomes of Helicobacter pylori eradication in patients receiving sequential therapy (ST) depending on the use of ecabet sodium (ES). MATERIALS AND METHODS: Between January to December 2015, 176 patients randomly received either ST alone (n=72) or 10-day ES therapy combined with ST (n=104). After applying the exclusion criteria, 56 patients were finally assigned to the ST-only group and 84 to the ST with ES group. We retrospectively reviewed and analyzed the H. pylori eradication rate and adverse events between the two groups. RESULTS: Among the 140 patients, 121 (86.4%) achieved successful H. pylori eradication and 24 (17.1%) had adverse events. Eradication was achieved in 50 patients (89.3%) in the ST-only group and in 71 patients (84.5%) in the ST with ES group (P=0.420). No significant difference in the incidence of adverse events was found between the ST-only and ST with ES groups (12.5% vs. 20.2%, respectively; P=0.234). However, the ST with ES group tended to have a higher prevalence of nausea or vomiting than the ST-only group (11.9% vs. 1.8%; P=0.050). CONCLUSIONS: ST showed a good H. pylori eradication rate without deteriorating the adverse events regardless of adding ES.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Sodio
/
Vómitos
/
Incidencia
/
Prevalencia
/
Estudios Retrospectivos
/
Helicobacter pylori
/
Helicobacter
/
Náusea
Tipo de estudio:
Incidence_studies
/
Observational_studies
/
Prevalence_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
Ko
Revista:
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Año:
2018
Tipo del documento:
Article